论文部分内容阅读
前列腺癌(PCA)是世界上男性最为流行的一种恶性肿瘤。美国每年约有28500人死于PCA,50岁以上的男性15%～50%患有隐性PCA。我国近年来资料显示PCA发病率也呈上升趋势。PCA早期无症状,晚期引起下尿路梗阻和骨转移时才为临床所注意。所以PCA的早期检出对治疗及预后具有关键作用。直肠镜内超声显像法是近年来诊疗前列腺癌的重要进展之一。一、直肠腔内超声显像(TRUS)及其引导下PCA活检术直肠指诊(DRE)、前列腺特异抗原(PSA)及TRUS技术是目前公认诊断PCA的主要方法。DRE迄今为止,依然是临床发现PCA的常规检查方法之一,但DRE对PCA诊断率不高,
Prostate cancer (PCA) is the most prevalent male cancer in the world. About 28,500 people in the United States die of PCA each year, and 15% to 50% of men over the age of 50 have implicated PCA. In recent years, China’s data show that the incidence of PCA also showed an upward trend. The early stage of PCA is asymptomatic, and it is only clinically noticeable that it causes lower urinary tract obstruction and bone metastasis later in life. Therefore, the early detection of PCA plays a key role in the treatment and prognosis. Rectal ultrasound imaging is one of the important advances in the treatment of prostate cancer in recent years. First, rectal cavity ultrasound imaging (TRUS) and guided PCA biopsy digital rectal examination (DRE), prostate specific antigen (PSA) and TRUS technology is currently recognized as the main method of diagnosis of PCA. The DRE has so far been one of the routine methods for the clinical detection of PCA, but the diagnostic rate of DRE for PCA is not high.